Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Objectives

To evaluate the long-term efficacy and safety of transobturator four-arm mesh for treating cystoceles.

Patients and methods

In this prospective study, 105 patients had a cystocele corrected between January 2004 and December 2008. All patients had a symptomatic cystocele of stage ⩾2 according to the Baden-Walker halfway stratification. We used only the transobturator four-arm mesh kit (Surgimesh®, Aspide Medical, France). All surgical procedures were carried out by the same experienced surgeon. The patients' characteristics and surgical variables were recorded prospectively. The anatomical outcome, as measured by a physical examination and postoperative stratification of prolapse, and functional outcome, as assessed by a questionnaire derived from the French equivalents of the Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire and the Pelvic Organ Prolapse-Urinary Incontinence-Sexual Questionnaire, were considered as the primary outcome measures. Peri- and postoperative complications constituted the secondary outcome measures.

Results

At 36 months after surgery the anatomical success rate (stage 0 or 1) was 93%. On a functional level, all the scores of quality of life and sexuality were improved. The overall satisfaction score (visual analogue scale) was 71.4%. There were no perioperative adverse events. Mesh erosion was reported in 7.6% and mesh retraction in 5.7% of the patients.

Conclusions

If the guidelines and precautions are followed, vaginal prosthetic surgery for genitourinary prolapse has shown long-term benefits. It provides excellent results both anatomically and functionally. However, complications are not negligible and some are specific to prosthetic surgery.

Free full text 


Logo of ajuArab Journal of Urology
Arab J Urol. 2014 Dec; 12(4): 275–284.
Published online 2014 Nov 11. https://doi.org/10.1016/j.aju.2014.09.007
PMCID: PMC4435760
PMID: 26019962

3-year results of transvaginal cystocele repair with transobturator four-arm mesh: A prospective study of 105 patients

Abstract

Objectives

To evaluate the long-term efficacy and safety of transobturator four-arm mesh for treating cystoceles.

Patients and methods

In this prospective study, 105 patients had a cystocele corrected between January 2004 and December 2008. All patients had a symptomatic cystocele of stage [gt-or-equal, slanted]2 according to the Baden–Walker halfway stratification. We used only the transobturator four-arm mesh kit (Surgimesh®, Aspide Medical, France). All surgical procedures were carried out by the same experienced surgeon. The patients’ characteristics and surgical variables were recorded prospectively. The anatomical outcome, as measured by a physical examination and postoperative stratification of prolapse, and functional outcome, as assessed by a questionnaire derived from the French equivalents of the Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire and the Pelvic Organ Prolapse–Urinary Incontinence-Sexual Questionnaire, were considered as the primary outcome measures. Peri- and postoperative complications constituted the secondary outcome measures.

Results

At 36 months after surgery the anatomical success rate (stage 0 or 1) was 93%. On a functional level, all the scores of quality of life and sexuality were improved. The overall satisfaction score (visual analogue scale) was 71.4%. There were no perioperative adverse events. Mesh erosion was reported in 7.6% and mesh retraction in 5.7% of the patients.

Conclusions

If the guidelines and precautions are followed, vaginal prosthetic surgery for genitourinary prolapse has shown long-term benefits. It provides excellent results both anatomically and functionally. However, complications are not negligible and some are specific to prosthetic surgery.

Abbreviations: VAS, visual analogue scale; TOT, transobturator tape; TVT, tension-free vaginal tape; TAPF, tendinous arch of the pelvic fascia; SUI, stress urinary incontinence; QoL, quality of life; PFDI, Pelvic Floor Distress Inventory; PPISQ-12, Pelvic Organ Prolapse/Urinary Incontinence-Sexual Questionnaire; PFDIQ, Pelvic Floor Distress Impact Questionnaire
Keywords: Genital prolapse, Cystocele, Transvaginal mesh, Polypropylene mesh

Introduction

Anterior genital prolapse or cystocele is a relaxation in the anterior vaginal wall, as described by De Lancey and Richardson [1]. Central and lateral cystoceles are distinguished according to the anatomical mechanism of connective tissue damage [2]. Lateral cystoceles are secondary to damage of the vaginal hammock fasteners to the pelvic wall at the level of the tendinous arch of the pelvic fascia (TAPF), whereas central cystoceles are secondary to the loss of support in the midline by Halban’s fascia [3]. The repair of anterior genital prolapse, whether or not associated with stress urinary incontinence (SUI), remains the weak point of vaginal surgery, with recurrence rates of 30–50% depending on the technical methods and reporting authors [4].

Formerly managed by simple subvesical plication or anterior colporrhaphy, more than a third of cystoceles recur. Indeed, the traditional colporrhaphy only corrects the central defects, and furthermore, adds a suture under tension to the poor quality of native tissues. These disadvantages have led to the development of more reliable and durable surgical techniques, resulting in the use of various types of mesh in vaginal prolapse surgery. These materials act as a frame, guiding the development of stronger supporting tissue [5,6]. Lightweight macroporous polypropylene meshes are currently the reference material, and are marketed in the form of sheets or pre-cut kits.

The objective of the present study was to evaluate the long-term safety and efficacy of cystocele treatment using a transobturator four-arm polypropylene mesh.

Patients and methods

In a prospective study at the authors’ institution patients who had a clinical diagnosis of cystocele and who underwent prosthetic surgery using a transobturator four-arm mesh were enrolled between 1 January 2004 and 31 December 2008. Informed consent was obtained from all patients and approval was obtained from the Ethics Committee of the hospital before the first surgical procedure.

All patients were questioned about their gynaecological, obstetric, surgical and pelvi-perineal history. The clinical examination aimed to reproduce the maximum degree of the anatomic prolapse, comprising a static part (gaping vulva, spontaneous exteriorisation of organs), and a dynamic part (externalisation during the Valsalva manoeuvre, or examination of SUI by coughing). Perineal testing and evaluation of the anal sphincter were systematic. Bonney or Ulmsten manoeuvres completed the examination if there was SUI.

Patients were included if they were aged >50 years; had a cystocele of [gt-or-equal, slanted]grade II according to the classification of Baden and Walker [7], either isolated or associated with prolapse of the other stages, either initial or recurrent; functional discomfort warranting surgery; and the consent of the patient.

Patients were excluded if they had a medical contraindication against the intervention, a urinary or genital recurrent infection, a history of pelvic irradiation or of malignant neoplasm of the lower urinary tract, long-term corticosteroid therapy or other immune deficiency, adnexal mass, neurological disorder affecting the stability of the bladder (multiple sclerosis, spinal cord injury), or an indication for laparotomy for other causes.

Procedure

Before surgery a urine sample was cultured, the pelvic area shaved and a cleansing enema given in all patients. We used the Surgimesh® prolapse kit (Aspide Medical, France) containing a macroporous monofilament polypropylene mesh of density 27.5 g/m2, and a set of transobturator tape (TOT) coil-type needles. The mesh is formed by a central portion shaped as a square of 5 cm2 and four lateral arms of 12 cm each. The width of these arms is reduced gradually to reach 5 mm at the ends (Fig. 1).

An external file that holds a picture, illustration, etc.
Object name is gr1.jpg

The polypropylene mesh, with a central part of 4–5 cm and four lateral wings of 12–13 cm long and 1 cm width. In front, the two needles used to make the tract for the mesh.

Technique

Spinal anaesthesia was preferred to general anaesthesia. Intravenous antibiotic prophylaxis (2 g cefazolin or amoxicillin/clavulanate) was routinely administered. The patient is placed in the dorsal lithotomy position, the buttocks slightly overlapping the table, and the thighs and legs in flexion. A large disinfection with povidone-iodine (or other non-iodised antiseptic in case of allergy) was used, and a permanent urinary catheter was placed (Fig.2).

An external file that holds a picture, illustration, etc.
Object name is gr2.jpg

The patient is placed in the dorsal lithotomy position, buttocks slightly overlapping the table, thighs and legs in flexion. Preoperative aspect, stage IV prolapse.

The anterior vaginal wall is exposed by traction on the cervix or on the vaginal cuff if there was a previous hysterectomy. The procedure began with infiltration of the vaginal wall with a solution of lidocaine 1% with adrenaline to help with the dissection plane and reduce bleeding. A vertical midline incision of the anterior vaginal wall is made from ≈2 cm below the urethral meatus to the cervix (or vaginal cuff if there was a previous hysterectomy). In cases of associated hysterectomy, a median colpotomy connected in a T-shape to the transverse colpotomy of the hysterectomy is then made. Apically and in the midline, the bladder is dissected all the way up and off the cuff of the vagina or the cervix if the uterus was in place. This dissection should repulse the bladder gradually. The fascia of Halban is held against the vaginal wall, leaving sufficiently thick tissue to cover the mesh after colporrhaphy. Laterally, the dissection is continued as far as possible, reaching the TAPF. This permits a large central and lateral exposure of the cystocele. In the space thus released, the implant is inserted between the vagina and bladder.

The transobturator phase begins with the preparation of the surgical path by inserting the tip of Mayo scissors (which is concave outward) between the puborectalis muscle and the ischiopubic branch, the relief of which is marked by bone contact with the scissors tip. A deep layer of triangular ligament is opened with a firm movement that provides access to the anterior extension of the ischiorectal space. The scissors are then opened and removed. Two skin incisions of 3 mm are made in the genito-femoral crease at the approximate level of the clitoral hood. The transobturator passage is tracked by palpation between the thumb and forefinger of the obturator membrane in contact with the ischio-pubic symphysis. The needle is introduced inwards, and punched through the obturator membrane, causing a marked ‘jump’. It must then bypass the ischio-pubic branch, and be brought with direct finger guidance, at the level of the proximal part of the TAFP (Fig.3). The mesh arms are then attached to the needles and then retracted from the groin incisions. A second pair of incisions is then made 3 cm inferior and 2 cm lateral to the superior incisions bilaterally. The needles are equipped in the same way as before, and are always introduced inwards. The needle is directed vertically, under finger guidance, to move behind the internal obturator muscle and emerge below the TAPF near its distal insertion, 1–2 cm distal to the ischial spine apically (Fig.4). The vaginal finger is used to apply pressure on the levator aponeurosis so that the needle can transfix it. The mesh arms are then attached to the needles and are retracted from the incisions. The implant must cover the entire dissected area. The arms are then adjusted and tightened in a tension-free fashion, considering the postoperative retraction of adjacent tissues. The prosthesis is fixed at two points with non-absorbable sutures placed in the pubic insertion of the levator. The portion of the vaginal section is closed by a running polyglactin 1/0 suture with no colpectomy. The procedure is completed by the mesh arms section (Fig.5).

An external file that holds a picture, illustration, etc.
Object name is gr3.jpg

The needle is introduced after a skin incision is made in the genito-crural line at the level of the urinary meatus, controlled by surgeon, below the ischiopubic ramus, punching it through the obturator membrane and externalising it through the vaginal incision (left side).

An external file that holds a picture, illustration, etc.
Object name is gr4.jpg

A second incision is made 3 cm inferior and 2 cm lateral to the superior incision. The needle is equipped in the same way as before, and is introduced inwards under finger guidance (left side).

An external file that holds a picture, illustration, etc.
Object name is gr5.jpg

The final aspect before the mesh arm section.

After surgery patients received systematic paracetamol (1 g every 6 h). If needed, it was associated with either NSAIDs (ketoprofen 100 mg every 8 h) or, in case of persistent pain, with morphine sulphate. The bladder catheter and vaginal packing were retained for 48 h. If stable, patients were discharged home 4 days after surgery. All patients received antibiotic treatment for 5 days, laxatives for 15 days, and vaginal antiseptics daily for a month. Anticoagulant therapy was given for 3 weeks from the date of surgery. Recommendations for local hygiene and sexual activity were given to patients systematically.

Evaluation of results

For the anatomical results, all patients had a clinical assessment before surgery according to the Baden and Walker stratification of prolapse [7], and all were re-examined at 4 weeks, 3 and 6 months, and then once a year after surgery. Only patients with stage 0 or 1 prolapse were considered as cured (stage I postoperative cystoceles were considered as physiological).

For the functional results, all patients completed self-administered questionnaires before and after surgery to assess symptoms, quality of life (QoL) and sexuality. This was repeated each time they were re-examined at the follow-up visits. The questionnaires used were the French equivalents of the Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Distress Impact Questionnaire (PFIQ) and the Pelvic Organ Prolapse–Urinary Incontinence-Sexual Questionnaire (PISQ-12) [8,9]. All patients had a systematic preoperative multichannel urodynamic assessment with reduction of the prolapse, according to the ICS standard [10].

When preoperative symptoms were associated with the four most common clinical variables (vaginal globus, pelvic heaviness, dyspareunia and urinary symptoms), the results of surgery were considered as ‘excellent’, if none of these symptoms were reported after surgery, as ‘good’ when any of the symptoms persisted, as ‘medium’ when two symptoms persisted, ‘poor’ when three symptoms persisted, and ‘bad’ when all four remained unchanged. An excellent or good result was considered as ‘success’.

Subjective outcomes were also assessed using a visual analogue scale (VAS, 0–10 on a horizontal ruler, with 0 = ‘very disappointed’ to 10 ‘very satisfied’). Patients responded to the question ‘How do you rate the results of the surgery?’, thus determining a score for overall satisfaction of 0–10.

Complications

We evaluated intraoperative (occurring during surgery), early and late complications. Early complications were defined as those that developed within 30 days after surgery and late as those observed [gt-or-equal, slanted]30 days after surgery. Clinical data were analysed using the chi-squared test or Fisher’s exact test when appropriate for qualitative variables, and Student’s t and Wilcoxon tests for quantitative variables, with < 0.05 considered to indicate statistical significance.

Results

In all, 105 women were included in the study, and their baseline demographic and clinical variables are shown in Table 1. The four most common preoperative symptoms reported were vaginal globus, found in all patients, pelvic heaviness in 99 (94%), dyspareunia in 91 (87%) and urinary symptoms in 86 (82%). These four signs were associated in 85 patients (81%) (Table 2). The correlations between urinary symptoms before surgery and the urodynamic assessment are shown in Table 3.

Table 1

The baseline demographic and clinical variables of the 105 patients.

VariableMean (SD, range) or n (%)
Age (years)63.4 (4.2, 52–73)
Parity3.2 (1.2, 1–8)
Body mass index (kg/m2)25.2 (4, 18.1–35.9)
Postmenopausal women103 (98)
Sexually activea82 (78)
Previous hysterectomy18 (17)


Previous three compartment prolapse repair16 (15)
 Abdominal route4 (4)
 Vaginal route12 (11)


Previous:
 Anterior vaginal wall repair only4 (4)
 Posterior colporrhaphy only7 (7)
 Anterior + posterior repair2 (2)
SUI procedure7 (7)
Burch colposuspension4 (4)
TVT3 (3)
aAt least one sexual intercourse per month.

Table 2

Subjective prolapse symptoms, as n (%), before and after surgery in the 105 patients.

SymptomBefore36 months afterP
Chronic pelvic pain12 (11)3 (3)<0.05
Pelvic heaviness99 (9412 (11)<0.05
Vaginal globus105 (100)4 (4)<0.05
Urinary symptoms86 (82)18 (17)<0.05
Urgency37 (35)12 (11)<0.05
SUI29 (28)2 (2)<0.05
(+2 de novo)
Dysuria20 (19)2 (2)<0.05
Sexually activea82 (78)74 (70)NS


With sexual intercourse:
 Pain28 (27)5 (5)<0.05
 Discomfort39 (37)2 (2)<0.05
Dyspareunia71 (68)12 (11)<0.05
(+2 de novo)
Difficulties in rectal voiding2 (2)0<0.05
Anal incontinence2 (2)2 (2)NS
Constipation35 (33)28 (27)NS
Dyschesia9 (9)5 (5)NS
All fourb85 (81)4 (4)<0.05

NS, not significant.

aWith at least one sexual intercourse/month.
bPelvic heaviness, vaginal globus, urinary symptoms, dyspareunia.

Table 3

Urinary symptoms before surgery, showing the correlation between clinical findings and urodynamic assessment.

Urodynamic assessment
Clinical findingsAll(a)(b)(c)(d)(a + c)(a + d)(b + d)Normal
SUI29145042220
Urgency37300250243
Dysuria20002000018
Normal19002300014

(a) Urethral hypermobility, (b) sphincter deficiency, (c) bladder hypocontractility, (d) detrusor overactivity.

All patients had [gt-or-equal, slanted]stage II cystocele according to the Baden and Walker stratification (Table 3). When prosthetic transvaginal cystocele repair was used alone the duration of surgery was 27 ± 2.3 min (ranges: 25–45 min). We performed 197 concomitant procedures, including 67 hysterectomies, 10 sacro-spinofixations (Richter procedure), 12 rectocele repairs by interposing a polypropylene prosthesis in the rectovaginal space and 14 by simple pre-rectus fascia plication, 75 perineal plasties associated with posterior levator myorrhaphy, and 19 treatments of SUI (according to clinical and urodynamic exploration) using a tension-free TOT. Patients underwent TOT as a concomitant procedure only when a physical assessment, objective SUI and urodynamic assessment showed urethral hypermobility or sphincter deficiency only. For all other cases (mixed urinary incontinence, bladder hypocontractility, etc.) the management of the urinary incontinence differed after cystocele repair. Suburethral tape was inserted in the same operative time at the end of the cystocele repair procedure, through a distinct vaginal incision, to avoid the risk of its displacement.

The intervention was feasible in all patients, and there were no intraoperative complications, e.g., haemorrhage or organ injury. The mean (SD) postoperative stay was 5 (2.2) days. Antibiotic prophylaxis and heparin therapy were instituted in all patients. The immediate and early postoperative adverse events are shown in Table 4. There were no postoperative haemorrhages or haematoma. Seven patients had fever on the first day after surgery that regressed spontaneously within 48–72 h, and six had transitory urinary retention. One patient had a postoperative levator myalgia that required short-term treatment with a muscle relaxant and anti-inflammatory agent. There were no postoperative infections of the mesh and no mesh had to be removed secondary to infection or pain.

Table 4

Immediate and late adverse events.

Adverse eventn (%)
Intraoperative complications
 Bladder injury0
 Rectal injury0
 Conversion0
 Blood transfusion0


Early postoperative complications (< 30 days)
 Fever7 (7)
 Haematoma0
 Urinary retention6 (6)
 De novo urinary incontinence2 (2)
 Mesh infection0
 Thrombophlebitis of the lower limb1 (1)


Late complications ([gt-or-equal, slanted]30 days)
 Mesh extrusion8 (8)
 Mesh retraction6 (6)
 De novo dyspareunia2 (2)
 Chronic pelvic pain2 (2)
 Chronic pain at the inner side of the thigh1 (1)
 Re-intervention related to pain or mesh erosion0

Late adverse events at a median (range) follow-up of 62 (41–92) months are shown in Table 4. Eight patients (8%) had a mesh extrusion due to healing defects. This complication occurred at 6 weeks to 4 months after surgery. In six cases local oestrogen therapy was sufficient treatment. In the two other patients surgery was required under local anaesthesia, and involved a minor procedure to excise the exposed mesh (the course was favourable, with no recurrences with a follow-up of >4 years). There was retraction of the prosthesis in six patients (6%), the diagnoses being made clinically by digital palpation in all cases. De novo dyspareunia was reported by two patients (2%) and these patients had an associated posterior repair with mesh. We also report two cases of de novo urinary incontinence (2%) and two of chronic pelvic pain (2%).

At 36 months after surgery all patients were available for a physical assessment and were able to complete both the symptoms and QoL questionnaires; there were no withdrawals during this period. The anatomical cure rate for cystocele was 93%, 43 patients (41%) having no cystocele, and 55 (52%) having a stage I cystocele. There were seven surgical failures (recurrent cystoceles; 7%), all at stage II (Table 5). Four of these recurrences were at 3–5 months after the treatment of a post-hysterectomy prolapse. No re-operation was done in these cases and only local oestrogen therapy was prescribed.

Table 5

Stratification of prolapse (Baden and Walker) before and after surgery.

Stage, n (%)
Prolapse0IIIIIIIV
Anterior compartment
 Before0010 (10)80 (76)15 (14)
 36 months after43 (41)55 (52)7 (7)00


Apical compartment
 Before8 (8)15 (14)25 (24)39 (37)18 (17)
 36 months after48 (46)46 (44)11 (11)00


Posterior compartment
 Before18 (17)19 (18)44 (42)18 (17)6 (6)
 36 months after25 (24)72 (69)9 (9)00

There was an improvement in the subjective prolapse symptoms after surgery. A favourable outcome was reported in all patients who had a TOT (no urinary incontinence or other urinary symptoms were reported). All the scores for the QoL and sexuality questionnaires also improved, as shown in Table 6. The overall satisfaction score (VAS) was 71.4%. Judging the results on the association of the four most common symptoms (vaginal globus, pelvic heaviness, urinary symptoms, dyspareunia), the success rate was 72.9%. There was a significant correlation between the success rate and satisfaction score (< 0.001).

Table 6

Pelvic discomfort, symptoms, QoL and sexuality scores before and after surgery.

AssessmentBefore36-monthsP
Pelvic discomfort VAS (0–10)7.61.8<0.05
PFDI
POPDI
 (0–100)51.0219.04<0.05
 Anterior (0–100)23.8110.01<0.05
 Posterior (0–100)35.9819.67<0.05
CRADI
 Obstructive (0–100)35.2514.00<0.05
 Incontinence (0–100)10.227.19NS
 Pain/irritative (0–100)30.1214.11<0.05
 Rectal prolapse (0–100)28.372.10<0.05
UDI
 Irritative symptoms (0–100)38.2811.23<0.05
 Obstructive/discomfort (0–100)43.228.39<0.05
 Stress symptoms (0–100)22.783.24<0.05
PFDIQ
POPIQ
 Physical activity (25–100)38.1526.10<0.05
 Social relationships (25–100)33.5526.50<0.05
 Travel (25–100)28.8827.10NS
 Emotional health (25–100)33.2825.22<0.05
CRAIQ
 Physical activity (25–100)29.6626.31NS
 Social relationships (25–100)25.1126.10NS
 Travel (25–100)28.3326.10NS
 Emotional health (25–100)28.1127.50NS
UIQ
 Physical activity (25–100)44.2824.48<0.05
 Social relationships (25–100)37.4034.05NS
 Travel (25–100)42.5922.32<0.05
 Emotional health (25–100)51.2525.33<0.05
PPISQ-12a27.5036.40<0.05

POPDI, pelvic organ prolapse distress inventory; CRADI, colo-rectal and anal distress inventory; UDI, urinary distress inventory; POPIQ, pelvic organ prolapse impact questionnaire; CRAIQ, colo-rectal and anal impact questionnaire; UIQ, urinary impact questionnaire. NS, not significant.

aCompleted by 74 patients.

Discussion

The use of mesh in vaginal prolapse surgery combines the advantages of abdominal sacral colpopexy with the low morbidity of vaginal surgery. The transobturator route was described by Delorme [11] in 2001 for the treatment of SUI, and then extended to genital prolapse. It is a minimally invasive surgery where the pelvic fasciae are spared [12]. The obturator foramen provides good security for the surgeon, and thus there is no major nerve or vascular elements in contact with the mesh [13,14].

Tayrac et al. [15] were among the first to use this route. They used a two-arm mesh, leaving its apical part in contact with the bladder unattached. The mesh could then retract its middle portion, and lead to long-term complications such as exposure, chronic pelvic pain, dyspareunia or recurrence of cystocele. Tayrac et al. [15] reported that the high rate of recurrence in the series could be attributed to this technique. The four-arm mesh technique was first described in 2004 by Palma et al. [16]. The dissection is the same as in the technique using two-arm mesh, and the bleeding risk is not increased. The result is a mesh that covers the whole extent of the bladder [17]. Intraoperative complications of transobturator route are mainly bleeding, and pelvic organ injuries (urethra, bladder, rectum or vagina) are exceptional [18,19] No intraoperative incident such as haemorrhage or organ injury was reported in the present series.

For the anatomical results several studies have shown the superiority of prosthetic surgery over traditional surgery, with an anatomical cure rate of 75–100% in the former [20]. Recurrence might be due to retraction of the mesh, failure of prosthetic support or to ageing of the patients [19]. We also think that the recurrence of cystocele is connected with a secondary displacement of the mesh. Indeed, mesh integration is a necessary condition for the correction of cystocele, and this is usually obtained in a few weeks. During this period a minimum of displacement is unavoidable. This is why some authors [21] suggest fixing the prosthesis after vaginal dissection with non-absorbable sutures, to cover the defect and prevent dislocation and deformation of the prosthesis. In case of recurrence, the removal of the prosthesis might be necessary and re-operation generally requires a different surgical technique. In the present series the anatomical success rate was 93%, and all recurrences (7%) were at stage II, with no re-operations.

All studies agree that there is a significant improvement in functional symptoms after prosthetic surgery. However, these results are similar to those of traditional surgery [22]. In the present series a significant improvement was reported on most of the subjective prolapse symptoms after surgery. Considering the results for the four most common symptoms, the success rate was 73%, and the overall satisfaction score was 71%.

Sexuality after vaginal prosthetic surgery has been the subject of several studies, with controversial results. The optimal time for sexual assessment should be at 6–12 months after surgery. It should ideally involve the partner, and the results must be considered in relation to the general population of the same age [23]. Khandwala et al. [24] and Eboue et al. [25] used the questionnaire on sexuality (PISQ-12) after surgery. The scores were improved in 22.9% and 24.4%, respectively, and unchanged in 85.7% and 57.8%. Surgery improved dyspareunia significantly in the series of Khandwala et al. [24] (48.1% before vs. 7.4% after surgery). The improvement in dyspareunia was also significant in the present series (86.6% before vs. 11% after). De novo dyspareunia can complicate vaginal surgery even if no meshes are used. Indeed, Carey et al. [26], in a randomised study comparing functional outcomes between the classic treatment of vaginal cystocele and after interposition of polypropylene mesh, found a significantly higher rate of dyspareunia in the group having a classic colporrhaphy. De novo dyspareunia was reported in 9–20% of patients after the treatment of cystocele with meshes [27]. We reported two cases of de novo dyspareunia (2%). The results of the present QoL and sexuality questionnaires were encouraging for the use of the type of mesh that we chose.

Urinary emergencies are often associated with cystocele. Symptomatic SUI is more associated with moderate prolapse, whilst an important prolapse is more often associated with obstructive phenomena. Eboue et al. [25], after a follow-up of 34 months, reported a significant improvement in SUI after cystocele was cured with a four-arm transobturator mesh. Long et al. [28] combined a tension-free vaginal tape (TVT) or TOT in patients with SUI. They reported a significant improvement in all urinary symptoms (SUI, urgency and dysuria). They recommended TOT rather than TVT due to the horizontal position of the strip, resulting in less postoperative dysuria. In all the present patients there was a significant improvement in dysuria (20 before vs. two after surgery, < 0.05) and urinary emergencies (37 vs. 12, respectively, < 0.05). All patients with SUI were surgically treated by the combination of a TOT and cystocele repair. The improvement in SUI was significant (19 vs. two, respectively, < 0.05). In our experience we never try to treat SUI by modifying the positioning of the ventral part of the mesh to be at the mid-urethral site, because we consider that the risk of mesh retraction or displacement might influence the outcome of the correction of SUI.

The most serious complication related to mesh is retraction. It can cause failure by restricting support areas, and secondary pain and dyspareunia caused by increased tension on the structures. The frequency of retractions is difficult to assess as there is no clear definition, but it is reported to be 11.7–17% [29]. In the present series the prosthesis retracted in six patients (6%). The retraction mechanism might be linked to several factors that lead to peri-prosthetic fibrosis. The occurrence of retraction depends on the mesh and on the inflammatory process after surgery. Its prevention requires the use of meshes with lighter composite materials. The diagnosis is made clinically or by transvaginal ultrasonography [22,30].

The exposure of the mesh is another specific complication of prosthetic surgery. Exposure occurs most frequently during the second month after surgery [21]. It is usually asymptomatic and discovered in the postoperative examination. However, it can cause minimal bleeding or vaginal discharge. The main cause of mesh exposure is colpectomy. Excision of the ‘excess’ of the vagina is usually done for aesthetic purposes. Vaginal tension sutures cause fragile scarring, increasing the risk of exposure [21]. In addition to colpectomy the type of incision seems to be important, mainly a T-incision (incision of Crossen) for hysterectomy [17]. Sergeant et al. [17] and Eboue et al. [25] also recommended that a ‘systematic’ hysterectomy not be used when treating genital prolapse. Bafghi et al. [31] proposed a circular incision of the anterior cervix with vesico-vaginal retrograde dissection instead of the conventional vertical colpotomy. Thus the insertion of the mesh is not located next to the incision. These authors [17,25,31] reported the following rates of exposure, respectively: 16%, 6.5% and 2%. In the present series the vertical colpotomy and T colpotomy, if associated with hysterectomy, gave an exposure rate of 7.6%. All patients with exposure had a concomitant hysterectomy. Lack of oestrogen also represents a risk factor for mesh exposure, thus some authors recommend systematic local oestrogen therapy before and after surgery [32,33]. Early sexual intercourse is another risk factor for exposure. Letouzey et al. [19] recommended a period of abstinence of 6 weeks after surgery. The treatment of mesh exposure is based on local oestrogen therapy to improve the trophicity of the vagina, associated with partial excision of the protruding portion of the mesh. However, if conservative treatment fails, surgical revision with total removal of the mesh might be necessary (1.5% of cases in the series of Letouzey et al. [19]). In the present series local oestrogen therapy was sufficient for six patients, and colpectomy with a partial excision was necessary in two. No patient required complete removal of the prosthesis.

Infections have become exceptional with the new implants. When they complicate an exposure of the mesh, more than half are treated medically. If infection persists beyond 2 months excision of the implant is required [34]. The prosthetic infection rate is 0–8% with or without previous exposure of the mesh [35]. A case of pelvic cellulitis was reported by Flood et al. [36] in 1998, and Cosson et al. [37] in 2005. Myers et al. [38] reported a case of pelvic abscess.

Chronic pelvic pain can also complicate prosthetic surgery. Pain is usually localised on the buttock, or at the groin [39]. Vaiyapuri et al. [40] reported 10.4% of patients had buttock pain and 22.6% had pain in the inner side of the thigh. The pain is due to the passage of the needle through the adductor muscles. Excessive traction on the arm of the mesh can also cause chronic vaginal pain. If pain persists beyond 6 months removal of the prosthesis becomes inevitable. Diagnosis and early treatment are necessary. In case of delay, even after removal of the prosthesis, the pain can persist due to irreversible nerve damage [21]. In the present series one patient reported chronic pain at the inner side of the thigh, but the course was favourable under anti-inflammatory treatment.

There are several limitations to the present study. The lack of a control arm and the relatively few patients could affect the statistical results and do not enable us to draw firm conclusions; more randomised studies involving many more patients are needed. We could not have precise data about the severity of SUI before surgery and the outcome of patients with mixed urinary incontinence after cystocele repair. On analysis of the results, demographic factors, which play an important role in recurrences and might explain postoperative complications, were not sufficiently investigated for correlation with the success or failure rates.

In conclusion, if the guidelines and precautions are followed, vaginal prosthetic surgery for genitourinary prolapse has shown long-term benefits. The transobturator route has a special place because of its low morbidity, excellent reproducibility and remarkable efficiency. Guidelines are now well established and involve even large cystoceles of stage III after the failure of other treatment methods. This route provides excellent results both anatomically and functionally. However, complications are not negligible and some are specific to prosthetic surgery. The first choice of mesh is currently the lightweight macroporous monofilament polypropylene mesh, but other materials, including composite and biological meshes are beginning to take their place on the market. Randomised studies comparing these materials with each other and with polypropylene are needed to improve the outcomes and reduce complications.

Conflict of interest

None.

Source of funding

None.

Footnotes

Peer review under responsibility of Arab Association of Urology.

References

1. De Lancey J.O.L., Richardson A.C. Anatomy of genital support. Clin Obstet Gynecol. 1993;36:19–33. [Google Scholar]
2. Richardson A.C., Lyon J.B., Williams N.L. A new look at pelvic relaxation. Am J Obstet Gynecol. 1976;126:568–573. [Abstract] [Google Scholar]
3. Olsen A., Smith V., Bergstrom J., Colling J.C., Clark A.L. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997;89:501–506. [Abstract] [Google Scholar]
4. Debodinance P., Amblard J., Fatton B., Cosson M., Jacquetin B. The prosthetic kits in the prolapse surgery: is it a gadget? J Gynecol Obstet Biol Reprod. 2007;36:267–275. [Abstract] [Google Scholar]
5. Sand P.K., Koduri S., Lobel R.W., Winkler H.A., Tomezsko J., Culligan P.J. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol. 2001;184:1357–1362. [Abstract] [Google Scholar]
6. Julian T.M. The efficacy of Marlex mesh in the repair of severe, recurrent vaginal prolapse of the anterior midvaginal wall. Am J Obstet Gynecol. 1996;175:1472–1475. [Abstract] [Google Scholar]
7. Baden W.F., Walker T.A., Lindsday H.J. The vaginal profile. Tex Med J. 1968;64:56–58. [Abstract] [Google Scholar]
8. De Tayrac R., Chauveaud-Lambling A., Fernandez D., Fernandez H. Quality of life instruments for women with pelvic organ prolapsed. J Gynecol Obstet Biol Reprod. 2003;32:503–507. [Abstract] [Google Scholar]
9. Rogers R.G., Coates K.W., Kammerer-Doak D., Khalsa S., Qalls C. A short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire (PISQ-12) Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:164–168. [Abstract] [Google Scholar]
10. Schäfer W., Abrams P., Liao L. International continence society good urodynamic practices. uroflowmetry, filling cystometry, and pressure-flow studies. Neurol Urodyn. 2002;21:261–274. [Abstract] [Google Scholar]
11. Delorme E. Transobturator urethral suspension. mini-invasive procedure in the treatment of stress urinary incontinence in women. Prog Urol. 2001;11:1306–1313. [Abstract] [Google Scholar]
12. Sergent F., Sentilhes L., Resch B., Diguet A., Verspyck E., Marpeau L. Prosthetic repair of genito-urinary prolapses by the transobturator infracoccygeal hammock technique: medium-term results. J Gynecol Obstet Biol Reprod. 2007;36:459–467. [Abstract] [Google Scholar]
13. Delorme E., Droupy S., De Tayrac R., Delmas V. Transobturator tape (Uratape). A new minimally invasive method in the treatment of urinary incontinence in women. Prog Urol. 2003;13:656–659. [Abstract] [Google Scholar]
14. Delmas V. Anatomical risks of transobturator suburethral tape in the treatment of female stress urinary incontinence. Eur Urol. 2005;48:793–798. [Abstract] [Google Scholar]
15. De Tayrac R., Deffieux X., Gervaise A., Chauveaud-Lambling A., Fernandez H. Long-term anatomical and functional assessment of transvaginal cystocele repair using a tension-free polypropylene mesh. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:483–488. [Abstract] [Google Scholar]
16. Palma P., Rane A., Riccetto C., Herrmann V., Dambros M., Tarazona A. Transobturator correction of cystocele. Actas Urol Esp. 2005;29:89–92. [Abstract] [Google Scholar]
17. Debodinance P., Berrocal J., Clavé H., Cosson M., Garbin O., Jacquetin B. Changing attitudes on the surgical treatment of urogenital prolapse: birth of the tension-free vaginal mesh. J Gynecol Obst Biol Reprod. 2004;33:577–588. [Abstract] [Google Scholar]
18. Maher C., Feiner B., Baessler K., Schmid C. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev. 2010:CD004014. [Abstract] [Google Scholar]
19. Deffieux X., Savary D., Letouzey V., Sentilhes L., Agostini A., Mares P. Prevention of the complications related to the use of prosthetic meshes in prolapse surgery: Guidelines for clinical practice – literature review. J Gynecol Obstet Biol Reprod. 2011;40:827–850. [Abstract] [Google Scholar]
20. Feldner P.C., Jr, Castro R.A., Cipolotti L.A., Delroy C.A., Sartori M.G., Girão M.J. Anterior vaginal wall prolapse: a randomized controlled trial of SIS graft versus traditional colporrhaphy. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21:1057–1063. [Abstract] [Google Scholar]
21. Von Theobald P. Place of mesh in vaginal surgery, including its removal and revision. Best Pract Res Clin Obstet Gynecol. 2011;25:197–203. [Abstract] [Google Scholar]
22. Barber M.D., Brubaker L., Nygaard I., Wheeler T.L., 2nd, Schaffer J., Chen Z. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol. 2009;114:600–609. [Europe PMC free article] [Abstract] [Google Scholar]
23. Fatton B. Sexual outcome after pelvic organ prolapse surgery. Prog Urol. 2009;19:1037–1059. [Abstract] [Google Scholar]
24. Khandwala S., Jayachandran C. Transvaginal mesh surgery for pelvic organ prolapse-prolift TM: a prospective clinical trial. Int Urogynecol J. 2011;22:1405–1411. [Abstract] [Google Scholar]
25. Eboue C., Marcus-Braun N., Von Theobald P. Cystocele repair by transobturator four arms mesh: monocentric experience of first 123 patients. Int Urogynecol J. 2010;21:85–93. [Abstract] [Google Scholar]
26. Carey M., Higgs P., Goh J., Lim J., Leong A., Krause H. Vaginal repair with mesh versus colporrhaphy for prolapse: a randomised controlled trial. BJOG. 2009;116:1380–1386. [Europe PMC free article] [Abstract] [Google Scholar]
27. Blandon R.E., Gebhart J.B., Trabuco E.C., Klingele C.J. Complications from vaginally placed mesh in pelvic reconstructive surgery. Int Urogynecol J. 2009;20:523–531. [Abstract] [Google Scholar]
28. Long C.Y., Hsu C.S., Jang M.Y., Liu C.M., Chiang P.H., Tsai E.M. Comparison of clinical outcome and urodynamic findings using “Perigee and/or Apogee” versus “Prolift anterior and/or posterior” system devices for the treatment of pelvic organ prolapse. Int Urogynecol J. 2011;22:233–239. [Abstract] [Google Scholar]
29. Milani A.L., Withagen M.I., Vierhout M.E. Trocar-guided total tension-free vaginal mesh repair of post-hysterectomy vaginal vault prolapsed. Int Urogynecol J. 2009;20:1203–1211. [Europe PMC free article] [Abstract] [Google Scholar]
30. Lucot J.P., Bot-Robin V., Girodet G., Rubod C., Boulanger L., Dedet B. Place du matériel prothétique dans le traitement du prolapsus par voie vaginale. Gynecol Obstet Biol Reprod. 2011;39:232–244. [Abstract] [Google Scholar]
31. Bafghi A., Lannelli A., Verger S., Novelas S., Amiel J., Gugenheim J. Transvaginal repair of genital prolapse with Prolift™: evaluation of safety and learning curve. J Gynecol Obstet Biol Reprod. 2009;38:77–82. [Abstract] [Google Scholar]
32. Achtari C., Hiscock R., O’Reilly B.A., Schierlitz L., Dwyer P.L. Risk factors for mesh erosion after transvaginal surgery using polypropylene (Atrium) or composite polypropylène/polyglactin 910 (Vypro II) mesh. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:389–394. [Abstract] [Google Scholar]
33. Bader G., Fauconnier A., Roger N., Heitz D., Ville Y. Cystocele repair by vaginal approach with a tension-free transversal polypropylene mesh. Technique and results. Gynecol Obstet Fertil. 2004;32:280–284. [Abstract] [Google Scholar]
34. Niro J., Philippe A.C., Jaffeux P., Amblard J., Velemir L., Savary D. Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh. Gynecol Obstet Fertil. 2010;38:648–652. [Abstract] [Google Scholar]
35. Simsiman A.J., Luber K.M., Menefee S.A. Vaginal paravaginal repair with porcine dermal reinforcement. Correction of advanced anterior vaginal prolapse. Am J Obstet Gynecol. 2006;195:1832–1836. [Abstract] [Google Scholar]
36. Flood C.G., Drutz H.P., Waja L. Anterior colporrhaphy reinforced with Marlex mesh for the treatment of cystoceles. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9:200–204. [Abstract] [Google Scholar]
37. Caquant F., Collinet P., Deruelle P., Lucot J.P., Cosson M. Perineal cellulitis following trans-obturator sub-urethral tape Uratape® Eur Urol. 2005;47:108–110. [Abstract] [Google Scholar]
38. Rardin C.R., Moore R., Ward R.M., Myers D.L. Recurrent thigh abscess with necrotizing fasciitis from a retained transobturator sling segment. J Minim Invasive Gynecol. 2009;16:84–87. [Abstract] [Google Scholar]
39. Moore R.D., Miklos J.R. Vaginal repair of cystocele with anterior wall mesh via transobturator route: efficacy and complications with up to 3-year followup. Adv Urol. 2009:743–831. [Europe PMC free article] [Abstract] [Google Scholar]
40. Vaiyapuri G.R., Han H.C., Lee L.C., Tseng L.A., Wong H.F. Use of the gynecare prolift system in surgery for pelvic organ prolapse: 1-year outcome. Int Urogynecol J. 2011;22:869–877. [Abstract] [Google Scholar]

Articles from Arab Journal of Urology: An International Journal are provided here courtesy of Taylor & Francis

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/54822152
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/54822152

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.aju.2014.09.007

Supporting
Mentioning
Contrasting
1
12
0

Article citations